United States Code

42 U.S.C. § 285c-2

Division Directors for Diabetes, Endocrinology, and Metabolic Diseases, Digestive Diseases and Nutrition, and Kidney, Urologic, and Hematologic Diseases; functions

Statute Watch

Get an alert when any bill in Congress would change this law — and every time it moves.

Sign in to follow →

Bills that would change it 9

  • HR 9169 PKD Cures Act Amends its part · introduced · 119th Congress
  • HR 8601 Liver Illness Visibility, Education, and Research Act of 2024 Amends · introduced · 118th Congress
  • HR 7585 Health Equity and Accountability Act of 2022 Amends its part 285c-2(a)(1) · introduced · 117th Congress
  • S 4486 Health Equity and Accountability Act of 2022 Amends its part 285c-2(a)(1) · introduced · 117th Congress
  • HR 5675 Liver Illness Visibility, Education, and Research Act of 2021 Amends · introduced · 117th Congress
  • S 3041 Liver Illness Visibility, Education, and Research Act of 2021 Amends · introduced · 117th Congress
  • S 3074 Liver Illness Visibility, Education, and Research Act of 2019 Amends · introduced · 116th Congress
  • HR 3016 Liver Illness Visibility, Education, and Research Act of 2019 Amends · introduced · 116th Congress
  • HR 5942 Health Equity and Accountability Act of 2018 Amends its part · introduced · 115th Congress

The law today

From the official United States Code, current through Public Law 119-121.

(a) (1) In the Institute there shall be a Division Director for Diabetes, Endocrinology, and Metabolic Diseases, a Division Director for Digestive Diseases and Nutrition, and a Division Director for Kidney, Urologic, and Hematologic Diseases. Such Division Directors, under the supervision of the Director of the Institute, shall be responsible for— (A) developing a coordinated plan (including recommendations for expenditures) for each of the national research institutes within the National Institutes of Health with respect to research and training concerning diabetes, endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic, and hematologic diseases; (B) assessing the adequacy of management approaches for the activities within such institutes concerning such diseases and nutrition and developing improved approaches if needed; (C) monitoring and reviewing expenditures by such institutes concerning such diseases and nutrition; and (D) identifying research opportunities concerning such diseases and nutrition and recommending ways to utilize such opportunities. (2) The Director of the Institute shall transmit to the Director of NIH the plans, recommendations, and reviews of the Division Directors under subparagraphs (A) through (D) of paragraph (1) together with such comments and recommendations as the Director of the Institute determines appropriate. (b) The Director of the Institute, acting through the Division Director for Diabetes, Endocrinology, and Metabolic Diseases, the Division Director for Digestive Diseases and Nutrition, and the Division Director for Kidney, Urologic, and Hematologic Diseases, shall— (1) carry out programs of support for research and training (other than training for which Ruth L. Kirschstein National Research Service Awards may be made under section 288 of this title) in the diagnosis, prevention, and treatment of diabetes mellitus and endocrine and metabolic diseases, digestive diseases and nutritional disorders, and kidney, urologic, and hematologic diseases, including support for training in medical schools, graduate clinical training, graduate training in epidemiology, epidemiology studies, clinical trials, and interdisciplinary research programs; and (2) establish programs of evaluation, planning, and dissemination of knowledge related to such research and training.
Official text at uscode.house.gov ↗